

ENDO PHARMACEUTICALS HOLDINGS INC

Form 8-K

February 20, 2003

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 20, 2003 (February  
19, 2003)

**ENDO PHARMACEUTICALS HOLDINGS INC.**

---

(Exact name of registrant as specified in its charter)

DELAWARE

39040

13-4022871

---

(State or other  
jurisdiction of  
incorporation)

(Commission File Number)

(I.R.S. Employer  
Identification No.)

100 Painters Drive  
Chadds Ford, Pennsylvania

19317

---

(Address of principal executive offices)

(Zip Code)

(610) 558-9800

---

(Registrant's telephone number, including area code)

N/A

---

(Former name or former address, if changed since last report)

---

**TABLE OF CONTENTS**

Item 7. Financial Statements and Exhibits.

Item 9. Regulation FD Disclosure.

SIGNATURES

INDEX TO EXHIBITS

PRESS RELEASE

---

**Table of Contents**

**Item 7. Financial Statements and Exhibits.**

(a) *Financial Statements of Business Acquired.*

Not applicable.

(b) *Pro Forma Financial Information.*

Not applicable.

(c) *Exhibits.*

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release of Endo Pharmaceuticals Holdings Inc. dated February 19, 2003

**Item 9. Regulation FD Disclosure.**

On February 19, 2003, the Registrant issued a press release, a copy of which is attached as Exhibit 99.1 to this Report and is incorporated herein by reference.

---

**Table of Contents**

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ENDO PHARMACEUTICALS HOLDINGS INC. (Registrant)

By:           /s/ CAROL A. AMMON          

Name: Carol A. Ammon  
Title: Chairman & Chief Executive Officer

Dated: February 20, 2003

---

**Table of Contents**

INDEX TO EXHIBITS

<b><u>Exhibit Number</u></b>	<b><u>Description</u></b>
99.1	Press Release of Endo Pharmaceuticals Holdings Inc. dated February 19, 2003